University of Alabama at Birmingham

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Alabama at Birmingham sits in the top decile of US sponsors by registered trial count (#26 of 15,742 sponsors by registered trial count).

1,160 total trials 216 currently recruiting 723 completed early-phase tilt top decile by trial count

University of Alabama at Birmingham: 1,160 sponsored US clinical trials, 216 recruiting.

University of Alabama at Birmingham sponsors 1,160 registered US clinical trials on ClinicalTrials.gov, 216 of them currently recruiting, and 723 completed. 97 of these trials are in Phase 3-4 (later-stage) and 259 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.

Top-decile sponsor footprint

University of Alabama at Birmingham ranks in the top decile of sponsors by registered trial count (#26 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 62/100

723 of 812 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,160 total, page 16 of 24

COMPLETED NA

The Snack Study: The Feasibility of Changing Night-time Food Choices to Improve Glucose Tolerance in Pregnancy

NCT02634593

TERMINATED Phase 1

Treatment of Macrophage Activation Syndrome (MAS) With Anakinra

NCT02780583

COMPLETED

Genetic Evaluation for Medication Selection (GEMS) Study

NCT03736057

COMPLETED Phase 2

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

NCT02538341

COMPLETED NA

A Carbohydrate-restricted Diet to Reverse Fatty Liver in Adolescents With Obesity

NCT02787668

TERMINATED NA

Smoking Cessation Tailored to Rural Young Adult African American Men:

NCT03808714

COMPLETED NA

Environmental or Nasal Cannula Oxygen for Preterm Infants Receiving Oxygen Therapy: a Randomized Cross-over Pilot Study

NCT02794662

COMPLETED NA

Effects of Diet on Brain Processing

NCT02835820

TERMINATED NA

A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1)

NCT02718131

COMPLETED NA

Outpatient Foley For Starting Induction of Labor at TErm

NCT02756689

COMPLETED NA

To Compare Free Gingival Grafts and Connective Tissue Grafts Around Implants With Lack of Keratinized Mucosa

NCT03338686

COMPLETED NA

Nocturnal Hypertension and Non-Dipping Blood Pressure

NCT03128177

COMPLETED Phase 2

Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children

NCT02707523

COMPLETED NA

Usefulness of A Scope Guide Assisted Colonoscopy Versus Conventional Colonoscopy

NCT02739893

COMPLETED NA

Pragmatic Airway Resuscitation Trial

NCT02419573

COMPLETED

Prospective Evaluation of Idiopathic Pancreatitis: Role of Endoscopic Ultrasonography

NCT00609726

COMPLETED NA

Late Permissive Hypercapnia for Intubated and Ventilated Preterm Infants

NCT02799875

COMPLETED NA

ENABLE CHF-PC (Comprehensive Heartcare For Patients and Caregivers)

NCT02505425

COMPLETED Phase 1

A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer

NCT02429843

COMPLETED

Natural History of Rett Syndrome & Related Disorders

NCT02738281

COMPLETED NA

Study of Dual-energy (DE) Contrast-enhanced (CE) Digital Mammography

NCT02995980

TERMINATED Phase 2

Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)

NCT02605616

COMPLETED Phase 3

Comparing Bupivacaine, Lidocaine, and a Combination of Bupivacaine and Lidocaine for Labor Epidural Activation

NCT03103100

COMPLETED NA

Dietary Prevention of Photodamage in Skin With Grapes

NCT02760160

COMPLETED NA

Overcoming TWEAK Signaling to Restore Muscle and Mobility After Joint Replacement

NCT02628795

COMPLETED NA

CARE Trial: Comparing Different Levels of Calorie Reduction for Weight Loss

NCT02736669

TERMINATED Phase 2

Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma

NCT02541903

COMPLETED NA

Real-World Evaluation of the Effect of Jublia on Nail Polish

NCT03022916

COMPLETED Phase 4

Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish

NCT03110029

COMPLETED Phase 4

Study Evaluating the Effect of Jublia on Dermatophytomas

NCT03098615

COMPLETED NA

Blue Light Photodynamic Therapy Treatment for Distal and Lateral Subungual Toenail Onychomycosis

NCT03022903

COMPLETED NA

Impact of Lowering Phosphate Additive Intake on Metabolism and Cardiovascular Health in Community-Living Adults

NCT02620449

COMPLETED NA

Home-Based Pulmonary Rehab for Patients With Pulmonary Fibrosis

NCT02600689

COMPLETED Phase 2

Mechanisms of Refractory Hypertension (Reserpine)

NCT03223272

COMPLETED NA

The Deep South IVR-based Active Lifestyle Study

NCT02627235

COMPLETED NA

Utility of Ultrasound in Identification of Midline and Placement of Epidural in Severely Obese Parturients

NCT03100968

COMPLETED NA

The Use of an Open Label Placebo to Treat Cancer Related Fatigue in Cancer Survivors

NCT02522988

COMPLETED Phase 4

Chronic Hypertension and Pregnancy (CHAP) Project

NCT02299414

TERMINATED NA

Breast VCEUS to Evaluate Early Response to Neoadjuvant Chemotherapy

NCT01817374

COMPLETED Early Phase 1

TOPIC Trial for COPD

NCT02135432

COMPLETED Phase 2

Psilocybin-facilitated Treatment for Cocaine Use

NCT02037126

COMPLETED NA

Influence of Ambient Temperature on Office Behaviors

NCT02507310

COMPLETED NA

The Role of Protein in Regulating Ad Libitum Energy Intake in Humans

NCT02613065

COMPLETED Phase 2

Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)

NCT02459119

COMPLETED NA

Gaming Console Home-Based Exercise for Adults With Cystic Fibrosis

NCT02277860

COMPLETED Phase 2

miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome

NCT02418195

COMPLETED NA

Community Influences Transitions in Youth Health (CITY) Health II - Center for the Study of Community Health

NCT04320186

COMPLETED NA

Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula

NCT02414204

COMPLETED

Interactive Videoconferencing in the Provision of Remote Peritoneal Dialysis

NCT02428803

COMPLETED Phase 1

University of Alabama at Birmingham (UAB) Adult CBD Program

NCT02700412

← Previous Page 16 of 24 Next →

Phase Distribution

PhaseTrial count
Phase 1 129
Phase 2 130
Phase 3 25
Phase 4 72

What is open in the University of Alabama at Birmingham pipeline

216 recruiting of 1,160 indexed (19% open); 723 completed (62%).

Phase mix: 97 late (III/IV) vs 259 early (I/II) (early-phase heavy).

Top condition: Obesity (15 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Alabama at Birmingham: open-pipeline peers nationwide

Peers matched on 1,160 registered trials and 19% open enrollment, not the therapeutic-area sidebar.

University of Alabama at Birmingham sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 15%16%17%18%19% Total trials Recruiting share University of Alabama at BirminghamNYU Langone HealthWake Forest University Health SciencesEmory UniversityNorthwestern UniversityUniversity of MinnesotaMclean HospitalChildren's Hospital Medical Center, CincinnatiArkansas Children's Hospital Research Institute
University of Alabama at Birmingham sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Alabama at Birmingham sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,160 trials (± recruiting share)

Sponsors near 19% open enrollment (± trial volume)

What to do with this University of Alabama at Birmingham page

1,160 registered trials is a research-attention snapshot, not an endorsement of University of Alabama at Birmingham or any single study.

  • 216 of University of Alabama at Birmingham's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition University of Alabama at Birmingham studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Alabama at Birmingham pipeline card: 1,160 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.